NEXMED

The future of GLP-1: pills and the next generation of medicines

GLP-1 pills are now a reality: the Wegovy pill is approved in the EU, orforglipron in the US. What's approved, what's coming next and what it means for you.

Nexmed Editorial · Updated 1 October 2026
The future of GLP-1: pills and the next generation of medicines

Weekly weight-loss injections have changed medicine in recent years. But research hasn't stopped: a new generation of treatments is on the way, with pills instead of injections and even more powerful molecules. This guide explains what's in the pipeline, what's already a reality and what "the future of GLP-1" means, in plain language.

In short (updated October 2026): GLP-1 weight-loss pills are now a reality. The Wegovy pill (oral semaglutide 25 mg) has been approved in the European Union since July 2026, and orforglipron (Foundayo) is approved in the US and the UK, but not yet in the EU. Retatrutide and CagriSema are still awaiting approval. None of these should be taken on your own initiative: availability and indications depend on regulators and on your doctor's decision.

Why "the next generation" matters

Current medicines (semaglutide, tirzepatide) have two practical limitations: they are injectable, and in many places they have been hard to get because of huge demand. An equally effective pill would solve the first problem (many people prefer pills to injections), and molecules that are easier to manufacture could help with availability. In addition, researchers are constantly looking for stronger and better-tolerated effects. Hence the race for the next generation.

Oral semaglutide: the injection becomes a pill

Semaglutide, the active substance in Ozempic and Wegovy, also comes as a tablet, in two versions:

  • Rybelsus, for type 2 diabetes, at lower doses.
  • The Wegovy pill (oral semaglutide 25 mg, once a day), for obesity. It was approved in the US in December 2025 and launched there in January 2026. The European Commission approved it on July 15, 2026, for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related complication. Launch dates and prices vary by country.

How effective is it? In the OASIS 4 trial (New England Journal of Medicine, 2025), oral semaglutide 25 mg led to an average weight loss of −13.6% over 64 weeks, versus −2.2% with placebo. The manufacturer often cites a figure of about 17%, but that refers only to patients who took the treatment as planned.

How is it taken? Because it is poorly absorbed, oral semaglutide has strict rules: usually in the morning, on an empty stomach, with a little water and at least 30 minutes before food, drinks or other medicines.

Switching from injections to the pill was analyzed recently in a study presented at EASD 2026. See what the OCTANE study shows.

Orforglipron: the "non-peptide" pill

Orforglipron (Eli Lilly) is a GLP-1 agonist that is not a peptide but a small molecule. It can be produced more easily than peptides and has no restrictions around meals or water: it can be taken at any time of day.

  • Approval: the FDA approved it on April 1, 2026, under the name Foundayo, for obesity. The UK authorized it on August 10, 2026, for obesity and type 2 diabetes, the first country in Europe to do so. It is not yet approved in the European Union.
  • Efficacy: in the ATTAIN-1 trial (New England Journal of Medicine, 2025), with 3,127 participants, the highest dose (36 mg) led to an average weight loss of −11.2% over 72 weeks, versus −2.1% with placebo. That's less than oral or injectable semaglutide, but the pill is simpler to take.

Retatrutide: the "triple agonist"

While current medicines act on one (semaglutide) or two (tirzepatide) receptors, retatrutide (Eli Lilly) goes further: it acts on three targets (the GLP-1, GIP and glucagon receptors).

  • In the phase 2 trial (New England Journal of Medicine, 2023), the highest dose led to an average weight loss of −24.2% over 48 weeks.
  • On September 29, 2026, the first phase 3 results were published in the New England Journal of Medicine (the TRIUMPH-1 trial, 2,339 adults with obesity and without diabetes, followed for 80 weeks). Average weight loss was −17.6% on 4 mg, −23.7% on 9 mg and −25.0% on 12 mg, versus −3.9% with placebo. Retatrutide also reduced pain in participants with knee osteoarthritis and breathing interruptions in those with sleep apnea. The most common side effects were gastrointestinal.
  • It is not approved anywhere. Products sold online as "retatrutide" are not the medicine tested in trials and have no quality control.

CagriSema and other combinations

Research is also exploring combinations of molecules that act in complementary ways, for example pairing semaglutide with cagrilintide (an amylin analog), known as CagriSema (Novo Nordisk).

  • In the REDEFINE 1 trial (New England Journal of Medicine, 2025), with 3,417 participants, the combination led to an average weight loss of −20.4% over 68 weeks, versus −3.0% with placebo.
  • It is not yet approved, in either the EU or the US.

These approaches show that the future is not about a single "winning" medicine, but about several options tailored to each patient.

What's already a reality and what's still in trials

It's important to distinguish between what you can use today and what has been announced:

Status as of October 2026:

MedicineFormEuropean UnionUS
Semaglutide (Ozempic, Wegovy)weekly injectionapprovedapproved
Tirzepatide (Mounjaro)weekly injectionapprovedapproved
Oral semaglutide 25 mg (the Wegovy pill)daily pillapproved (July 2026)approved (December 2025)
Orforglipron (Foundayo)daily pillnot approved (approved in the UK)approved (April 2026)
CagriSemaweekly injectionnot approvednot approved
Retatrutideweekly injectionnot approvednot approved

Approval does not mean the medicine is already on pharmacy shelves in your country. Confirm availability and price with your doctor and pharmacy. For the right long-term dose, see also the guide to the minimum effective dose.

What this means for patients

For anyone interested in weight management, the direction is encouraging: more options, more convenient and potentially more effective. But a few principles stay the same:

  • All of these medicines are prescription-only and require a medical evaluation.
  • None of them is an effortless "magic solution": they work best alongside lifestyle changes.
  • Side effects (especially gastrointestinal) and contraindications apply to the whole class.
  • "New" doesn't automatically mean "better for you": the right fit depends on your individual profile.

Beware of hype and unofficial sources

The enthusiasm around these medicines also attracts misinformation and dangerous products. As new molecules appear, expect a wave of "versions" sold through unofficial channels, often counterfeit or unsafe. The rule stays firm: only with a prescription and only from licensed pharmacies. A "next-generation" medicine bought online may, in fact, be a next-generation risk.

The bigger picture

Beyond each individual molecule, the trend says something important about medicine: obesity and metabolic diseases are increasingly treated as serious chronic conditions, with real treatment options, not as failures of willpower. The new generation of medicines expands this toolkit. It remains essential that these tools are used responsibly, under medical supervision, as part of a comprehensive approach to health.

Questions to ask your doctor

If you're interested in weight management and hear about these new options, a structured conversation with your doctor helps you separate reality from hype:

  • Which of these options is available now where I live, for my situation?
  • What practical difference would a pill make for me compared with an injection?
  • What are the side effects and contraindications in my case?
  • How long would treatment last, and what happens when I stop?
  • How does it fit with the lifestyle changes I should make?

These questions move the conversation from "what's trendy" to "what's right for me".

How it could change access to treatment

Beyond efficacy, an important practical factor is access. Injectables have been hard to get and expensive in many places. Oral molecules that are easier to manufacture, such as orforglipron, could over time increase availability and ease pressure on supply. This matters enormously for patients: an effective treatment that is unaffordable or constantly out of stock helps few people. If the new generation brings options that are easier to produce and take, the real benefit could be not just "more effective" but also "reaches more of the people who need it". It remains to be seen how these promises will translate into actual prices, insurance coverage and availability.

Whether you take a weekly injection or, later, a daily pill, a GLP-1 tracker app such as Reko (partner app, iPhone) keeps your doses, side effects and weight in one private record you can show your doctor.

Conclusion

The future of GLP-1 brings pills instead of injections and ever more powerful molecules: oral semaglutide, orforglipron, retatrutide and new combinations. Some are already here; others are close. For patients, this means more options and more convenience, but the same basic rules: a prescription, medical supervision, a healthy lifestyle and caution about unofficial sources. The field is moving fast, and the best compass remains the conversation with your doctor.

What stays the same

In the rush for what's new, it's easy to forget what doesn't change. However advanced a medicine becomes, a few truths still hold: a healthy weight is built on diet, physical activity and sleep; no medicine works to its full potential without these foundations; and stopping treatment usually leads to regaining some of the weight if habits haven't changed. In other words, the new generation of medicines offers better tools, but it doesn't remove the need for a comprehensive approach. The best result comes from combining the right treatment, under medical supervision, with lasting lifestyle changes, an idea that will never go out of date.

Frequently asked questions

Is there already a GLP-1 weight-loss pill? Yes. The Wegovy pill (oral semaglutide 25 mg) has been approved in the European Union since July 15, 2026, and in the US since December 2025. Orforglipron (Foundayo) is approved in the US and the UK, but not in the EU. Confirm availability where you live with your doctor and pharmacy.

What is orforglipron (Foundayo)? A "non-peptide" GLP-1 agonist (a small molecule) in pill form, which can be taken at any time, with no restrictions around meals or water. It was approved in the US in April 2026 and in the UK in August 2026. It is not yet approved in the EU.

What is retatrutide? A "triple agonist" (GLP-1, GIP, glucagon) that has produced some of the largest weight losses seen with any medicine: −25.0% on average on the 12 mg dose in the phase 3 TRIUMPH-1 trial (published in September 2026). It is not yet approved anywhere.

Are the pills as effective as the injections? It depends on the pill. Oral semaglutide 25 mg led to −13.6% in OASIS 4, close to the Wegovy injection (−14.9% in STEP 1). Orforglipron led to −11.2% in ATTAIN-1. Comparisons across different trials should be made with caution. Your doctor will recommend what fits.

Are these medicines safer? They belong to the same class and generally have a similar side-effect profile (mainly gastrointestinal) and contraindications. "New" doesn't automatically mean "safer for you".

Can I buy them online? No. They are prescription medicines; buying from unofficial sources is risky (counterfeit or unsafe products). Only from licensed pharmacies, with a prescription.

When will the new medicines be available? The Wegovy pill is approved in the EU and the US, but launch dates and prices vary by country. Orforglipron, CagriSema and retatrutide are not yet approved in the EU. Confirm the current situation with your doctor and pharmacy.

Should I wait for the next generation instead of starting treatment now? Don't put off a medical decision based on what "might come next". Discuss the options available today with your doctor; the right treatment now is worth more than a hypothetical one in the future.

Read also

Sources

  • Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393:1077-1087. doi:10.1056/NEJMoa2500969
  • Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. doi:10.1056/NEJMoa2511774
  • Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393:635-647. doi:10.1056/NEJMoa2502081
  • Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972
  • Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169
  • European Commission: authorization of the Wegovy pill (July 15, 2026); FDA: approval of Foundayo (April 1, 2026); MHRA: authorization of orforglipron (August 10, 2026).

Educational content, updated October 2026. It does not replace medical advice. The approval status and availability of these medicines differ by country and change over time; confirm with your doctor and pharmacy.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1